ElleS review

ElleS Care connects patients with outside licensed healthcare professionals rather than manufacturing compounded medication. Its current public terms identify the operator and allow payment processing by an affiliate or third-party processor. The rendered homepage names Lion MD as a medical team and lists two lead physicians, but those descriptions do not establish which practice and practitioner will treat an individual patient. Confirm the actual assignment and the clinician’s authorization for the patient’s physical location. A published professional profile or platform-wide clinical representation is a useful starting point rather than verification of every encounter or preparation.

The current product cards show more than one payment scope. Standard semaglutide and tirzepatide injections, oral capsules and several longevity products have one-, three-, six- and twelve-month options, with the displayed starting amount identified as maximum savings on the longest plan. Microdose cards can instead show only a one-month option. The lowest homepage starting figure therefore should not be treated as the ongoing full-dose medication price or a freely cancelable single-month purchase. Obtain the exact charge due now, commitment, later renewal amount and supply. Normalized comparisons remain unquoted until the selected agreement resolves those details.

The longevity tab lists NAD+ injections, nasal spray and tablets, plus sermorelin injection and orally dissolving formats. These share a displayed starting figure tied to longer-plan savings, but a matching starting price does not prove the same total for every plan or make the formats clinically equivalent. The NAD+ detail modal says consultation, medication and shipping are included if prescribed, while a separate telehealth consultation fee applies when medication is not prescribed. A free assessment is therefore different from free completed clinical review in every circumstance. Check the selected treatment’s refusal fee and any other charges before authorizing the assessment.

The care workflow begins with a free online assessment, followed by clinician review and a short telehealth visit when needed. The homepage says some patients are approved without a call; it does not guarantee that no live assessment, testing or additional questions will ever be required. If prescribed, medication is shipped with tracked delivery and ongoing support is described as included. Delivery and eligibility remain subject to clinical decisions and pharmacy availability. Products carrying limited-stock labels should not be treated as guaranteed access. Company claims about stable prices across dose changes need confirmation for the actual agreement and formulation.

The pharmacy FAQ lists Belmar, Strive, Epiq Scripts and Casa Pharma Rx with telephone numbers. It does not establish which specific dispensing location handles a patient’s order, and the correct site matters when verifying licenses and destination-state authorization. The general state FAQ promotes nationwide access while expressly warning that individual services vary by licensure and regulations. Obtain the actual pharmacy identity and product-specific state eligibility rather than assuming the network name or nationwide marketing resolves every location. The homepage also includes testimonials referring to another care brand; those quotes should not be treated as verified personal outcomes from the selected ElleS preparation.

Cancellation is less specific than the marketing suggests. The homepage says no subscription or long-term commitment, while the product cards promote longer plans. The public service terms authorize charges under the applicable payment arrangement but do not spell out a complete refund, early-cancellation or renewal policy. Ask whether a longer option is prepaid, installment-based or simply a discounted supply, and what remains due after treatment stops. Request the clinical-refusal charge, pharmacy-processing cutoff and unused-plan policy in writing. Compounded GLP-1 and longevity listings also do not establish equivalence to approved medicines or a proven benefit from microdose and alternate-route preparations.